EA201691982A1 - 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов - Google Patents
5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторовInfo
- Publication number
- EA201691982A1 EA201691982A1 EA201691982A EA201691982A EA201691982A1 EA 201691982 A1 EA201691982 A1 EA 201691982A1 EA 201691982 A EA201691982 A EA 201691982A EA 201691982 A EA201691982 A EA 201691982A EA 201691982 A1 EA201691982 A1 EA 201691982A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- carboxamides
- agonists
- disposable
- pyridine
- cannabinoid receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
Настоящее изобретение относится к соединению формулы (I)где R-Rявляются такими, как определено в описании или формуле изобретения. Соединение формулы (I) может применяться в качестве лекарственного средства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14163554 | 2014-04-04 | ||
PCT/EP2015/057144 WO2015150438A1 (en) | 2014-04-04 | 2015-04-01 | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691982A1 true EA201691982A1 (ru) | 2017-01-30 |
EA030032B1 EA030032B1 (ru) | 2018-06-29 |
Family
ID=50424142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691982A EA030032B1 (ru) | 2014-04-04 | 2015-04-01 | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов |
Country Status (18)
Country | Link |
---|---|
US (2) | US20160376237A1 (ru) |
EP (1) | EP3126349B1 (ru) |
JP (1) | JP6353072B2 (ru) |
KR (2) | KR20160132495A (ru) |
CN (2) | CN106458984A (ru) |
AR (1) | AR099932A1 (ru) |
AU (1) | AU2015239537B2 (ru) |
CA (1) | CA2944256A1 (ru) |
CL (1) | CL2016002389A1 (ru) |
CR (1) | CR20160459A (ru) |
EA (1) | EA030032B1 (ru) |
IL (1) | IL247773A0 (ru) |
MX (1) | MX2016012690A (ru) |
PE (1) | PE20161407A1 (ru) |
PH (1) | PH12016501849A1 (ru) |
SG (1) | SG11201608246VA (ru) |
TW (1) | TW201625538A (ru) |
WO (1) | WO2015150438A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2899168A1 (en) | 2013-03-26 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
LT3126354T (lt) | 2014-04-04 | 2020-03-25 | H. Lundbeck A/S | Halogeninti kvinazolin-thf-aminai kaip pde1 inhibitoriai |
AU2016368475B2 (en) | 2015-12-09 | 2021-03-04 | F. Hoffmann-La Roche Ag | Phenyl derivatives as cannabinoid receptor 2 agonists |
GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
EP3642200B1 (en) | 2017-06-20 | 2023-05-03 | F. Hoffmann-La Roche AG | Pyridine derivatives |
KR20210028202A (ko) * | 2018-06-27 | 2021-03-11 | 에프. 호프만-라 로슈 아게 | 칸나비노이드 수용체 2의 억제제로서 신규한 피리딘 및 피라진 화합물 |
JP7454512B2 (ja) | 2018-06-27 | 2024-03-22 | エフ. ホフマン-ラ ロシュ アーゲー | 優先的カンナビノイド2アゴニストとしてのピリジン及びピラジン誘導体 |
WO2020002280A1 (en) * | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
WO2023145372A1 (ja) * | 2022-01-28 | 2023-08-03 | 日本曹達株式会社 | アミド化合物の製造方法 |
CN115160306B (zh) * | 2022-08-04 | 2024-03-26 | 上海皓鸿生物医药科技有限公司 | 一种特力利汀中间体的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2664621A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives |
WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
EP3357918A1 (en) * | 2012-12-07 | 2018-08-08 | F. Hoffmann-La Roche AG | Novel pyridine derivatives |
US9303012B2 (en) * | 2012-12-07 | 2016-04-05 | Hoffman-La Roche Inc. | Pyridine-2-amides useful as CB2 agonists |
-
2015
- 2015-04-01 EA EA201691982A patent/EA030032B1/ru not_active IP Right Cessation
- 2015-04-01 JP JP2016560828A patent/JP6353072B2/ja active Active
- 2015-04-01 AU AU2015239537A patent/AU2015239537B2/en not_active Expired - Fee Related
- 2015-04-01 SG SG11201608246VA patent/SG11201608246VA/en unknown
- 2015-04-01 KR KR1020167030794A patent/KR20160132495A/ko not_active Application Discontinuation
- 2015-04-01 PE PE2016001892A patent/PE20161407A1/es unknown
- 2015-04-01 AR ARP150100984A patent/AR099932A1/es unknown
- 2015-04-01 CA CA2944256A patent/CA2944256A1/en not_active Abandoned
- 2015-04-01 KR KR1020187016509A patent/KR20180072827A/ko not_active Application Discontinuation
- 2015-04-01 CN CN201580016783.5A patent/CN106458984A/zh active Pending
- 2015-04-01 CR CR20160459A patent/CR20160459A/es unknown
- 2015-04-01 WO PCT/EP2015/057144 patent/WO2015150438A1/en active Application Filing
- 2015-04-01 EP EP15712968.5A patent/EP3126349B1/en active Active
- 2015-04-01 CN CN202010029759.8A patent/CN111170938A/zh active Pending
- 2015-04-01 MX MX2016012690A patent/MX2016012690A/es unknown
- 2015-04-02 TW TW104111028A patent/TW201625538A/zh unknown
-
2016
- 2016-09-09 US US15/260,819 patent/US20160376237A1/en not_active Abandoned
- 2016-09-12 IL IL247773A patent/IL247773A0/en unknown
- 2016-09-21 PH PH12016501849A patent/PH12016501849A1/en unknown
- 2016-09-22 CL CL2016002389A patent/CL2016002389A1/es unknown
-
2018
- 2018-07-20 US US16/041,641 patent/US20180327360A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20180072827A (ko) | 2018-06-29 |
EA030032B1 (ru) | 2018-06-29 |
MX2016012690A (es) | 2017-04-27 |
CL2016002389A1 (es) | 2017-03-17 |
AU2015239537A1 (en) | 2016-11-17 |
SG11201608246VA (en) | 2016-10-28 |
IL247773A0 (en) | 2016-11-30 |
EP3126349A1 (en) | 2017-02-08 |
US20180327360A1 (en) | 2018-11-15 |
CN106458984A (zh) | 2017-02-22 |
AR099932A1 (es) | 2016-08-31 |
EP3126349B1 (en) | 2019-06-26 |
TW201625538A (zh) | 2016-07-16 |
CR20160459A (es) | 2016-12-02 |
KR20160132495A (ko) | 2016-11-18 |
JP2017509688A (ja) | 2017-04-06 |
WO2015150438A1 (en) | 2015-10-08 |
CA2944256A1 (en) | 2015-10-08 |
AU2015239537B2 (en) | 2019-04-04 |
US20160376237A1 (en) | 2016-12-29 |
JP6353072B2 (ja) | 2018-07-04 |
PH12016501849A1 (en) | 2016-12-19 |
CN111170938A (zh) | 2020-05-19 |
PE20161407A1 (es) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691982A1 (ru) | 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов | |
EA201891211A1 (ru) | Ингибиторы cxcr2 | |
EA201791299A1 (ru) | Микроинкапсулированные композиции каннабиноидов | |
EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
EA201600091A1 (ru) | 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов | |
EA201692219A1 (ru) | Способы получения противовирусных соединений | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
EA201891336A1 (ru) | Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj | |
TR201907981T4 (tr) | Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı. | |
EA201590854A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
EA201591624A1 (ru) | Новые производные пиразола | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
EA201790939A1 (ru) | ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2 | |
EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
CO2018004573A2 (es) | Derivados de fenilo como agonistas del receptor 2 de cannabinoides | |
CL2015002358A1 (es) | Compuestos bicíclicos. | |
CR20150417A (es) | Compuestos de azetidiniloxifenilpirrolidina | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
BR112016027455A2 (pt) | moduladores ppar | |
ECSP16096831A (es) | Derivados de naftiridinadiona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |